In both analyses, each region has three stages of increasing abnormality relative to a control group that is expected to be at minimal risk of Alzheimer’s disease (in both cases: amyloid-negative, APOE ε4−, cognitively normal participants). The gene discussed is APOE; the disease is Alzheimer disease.